Luhan Pharmachem Co., Ltd.

Luhan pharmachem Co., Ltd. supplies Selexipag bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.

Selexipag is a drug developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation. The USFDA granted selexipag Ophan status for PAH. It was approved by the US FDA on 22 December 2015.